EYE vs HSIC vs NVST vs XRAY

For growth investors, National Vision Holdings, Inc.

(EYE) is the stronger pick with 9. 0% revenue growth year-over-year, versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate National Vision Holdings, Inc. (EYE) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Henry Schein, Inc.

(HSIC) is the cheapest at 21. 6x versus Envista Holdings Corp at 86. 7x. On forward P/E, DENTSPLY SIRONA Inc. is actually cheaper at 7. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Henry Schein, Inc. wins at 4. 21x versus Envista Holdings Corp's 11. 53x.

Over the past 5 years, Henry Schein, Inc.

(HSIC) delivered a total return of -12. 5%, compared to -80. 1% for DENTSPLY SIRONA Inc. (XRAY). Over 10 years, the gap is even starker: HSIC returned +5. 3% versus XRAY's -74. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Henry Schein, Inc.

(HSIC) is the lower-risk stock at 0. 73β versus DENTSPLY SIRONA Inc. 's 1. 78β — meaning XRAY is approximately 144% more volatile than HSIC relative to the S&P 500. On balance sheet safety, Envista Holdings Corp (NVST) carries a lower debt/equity ratio of 55% versus 184% for DENTSPLY SIRONA Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), National Vision Holdings, Inc.

(EYE) is pulling ahead at 9. 0% versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). On earnings-per-share growth, the picture is similar: National Vision Holdings, Inc. grew EPS 202. 8% year-over-year, compared to 7. 2% for Henry Schein, Inc.. Over a 3-year CAGR, EYE leads at 6. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Henry Schein, Inc.

(HSIC) is the more profitable company, earning 3. 0% net margin versus -16. 3% for DENTSPLY SIRONA Inc. — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVST leads at 8. 3% versus 3. 1% for EYE. At the gross margin level — before operating expenses — NVST leads at 55. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Henry Schein, Inc. (HSIC) is the more undervalued stock at a PEG of 4. 21x versus Envista Holdings Corp's 11. 53x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, DENTSPLY SIRONA Inc. (XRAY) trades at 7. 7x forward P/E versus 32. 6x for National Vision Holdings, Inc. — 24. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EYE: 54. 2% to $35. 20.

In this comparison, XRAY (5.

9% yield) pays a dividend. EYE, HSIC, NVST do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Henry Schein, Inc.

(HSIC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 73)). Envista Holdings Corp (NVST) carries a higher beta of 1. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HSIC: +5. 3%, NVST: -13. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EYE (Consumer Cyclical) and HSIC (Healthcare) and NVST (Healthcare) and XRAY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EYE is a small-cap quality compounder stock; HSIC is a small-cap quality compounder stock; NVST is a small-cap quality compounder stock; XRAY is a small-cap income-oriented stock. XRAY pays a dividend while EYE, HSIC, NVST do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.